164 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up http://www.zacks.com/stock/news/290293/abbvie-abbv-q4-earnings-beat-2018-view-raised-shares-up?cid=CS-ZC-FT-290293 Jan 26, 2018 - AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Will Sanofi's Big Hemophilia Deal Pay Off? https://www.fool.com/investing/2018/01/24/will-sanofis-big-hemophilia-deal-pay-off.aspx?source=iedfolrf0000001 Jan 24, 2018 - Sanofi's leap into an undeniably big market could face challenges as treatment evolves.
Biotech M&A Off to a Strong Start in 2018: More Deals to Follow? http://www.zacks.com/stock/news/289649/biotech-ma-off-to-a-strong-start-in-2018-more-deals-to-follow?cid=CS-ZC-FT-289649 Jan 23, 2018 - Does Celgene's (CELG) decision to acquire Juno signal the revival of biotech M&A activity after a slow 2017?
Better Buy: GlaxoSmithKline plc vs. Eli Lilly https://www.fool.com/investing/2018/01/21/better-buy-glaxosmithkline-plc-vs-eli-lilly.aspx?source=iedfolrf0000001 Jan 21, 2018 - Both big pharma stocks have growth drivers. But both also come with baggage.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis http://www.zacks.com/stock/news/289410/the-zacks-analyst-blog-highlights-johnson-johnson-abbvie-amgen-novo-nordisk-and-zoetis?cid=CS-ZC-FT-289410 Jan 19, 2018 - The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18? http://www.zacks.com/stock/news/289345/can-these-4-large-cap-drug-stocks-deliver-an-encore-in-18?cid=CS-ZC-FT-289345 Jan 18, 2018 - We present four large cap drug companies, which are expected to repeat their last year's industry beating performance in 2018.
Is Eli Lilly and Company a Buy in 2018? https://www.fool.com/investing/2018/01/17/is-eli-lilly-and-company-a-buy-in-2018.aspx?source=iedfolrf0000001 Jan 17, 2018 - The outlook is complicated for this big pharma stock.
Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It? http://www.zacks.com/stock/news/289135/novo-nordisks-nvo-hits-52-week-high-whats-driving-it?cid=CS-ZC-FT-289135 Jan 17, 2018 - Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.
Teva's Trisenox Gets FDA Approval as First-Line Treatment http://www.zacks.com/stock/news/288993/tevas-trisenox-gets-fda-approval-as-first-line-treatment?cid=CS-ZC-FT-288993 Jan 16, 2018 - Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.
Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU http://www.zacks.com/stock/news/288847/foreign-stock-roundup-infosys-beats-astrazenecas-asthma-drug-gets-approval-in-eu?cid=CS-ZC-FT-288847 Jan 15, 2018 - Global markets endured a volatile week, guided by opposing factors.

Pages: 1...4567891011121314...17

<<<Page 9>